Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2024-06-24 00:00:00 ET · period of report 2024-06-20 · accession 0000950170-24-076468 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-24 | 2024-06-20 | NAMS | Davidson Michael H. | CEO, Dir | P - Purchase | $17.26 | +5,000 | 204.8K | +3% | +$86.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-06-20 | P | A | 5,000 | $17.26 | 204,784 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.115 to $17.60, inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, specific trade amounts and pricing within the range set forth in this footnote at which the transaction was effected. |